Search Results - "LONIAL, S"

Association of response endpoints with survival outcomes in multiple myeloma by Lonial, S, Anderson, K C

“…Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple…”
Get full text

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives by Lonial, S, Durie, B, Palumbo, A, San-Miguel, J

“…The treatment landscape for patients with multiple myeloma (MM) is constantly evolving. Over the past decade, the introduction of novel agents such as…”
Get full text

What is the Role for Monoclonal Antibodies in MM? What do the Preclinical Data tell us? by Lonial, S

Get full text

IMiD-based Triplet Therapy for Multiple Myeloma by Lonial, S

Get full text

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients by Nooka, A K, Kaufman, J L, Muppidi, S, Langston, A, Heffner, L T, Gleason, C, Casbourne, D, Saxe, D, Boise, L H, Lonial, S

“…Prior studies have shown that myeloma patients exhibiting either genetically defined high-risk disease or plasma cell leukemia have a poor outcome with a…”
Get full text

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies by Siegel, David, Martin, Thomas, Nooka, Ajay, Harvey, R Donald, Vij, Ravi, Niesvizky, Ruben, Badros, Ashraf Z, Jagannath, Sundar, McCulloch, Leanne, Rajangam, Kanya, Lonial, Sagar

“…Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent…”
Get full text

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma by Miller, A, Asmann, Y, Cattaneo, L, Braggio, E, Keats, J, Auclair, D, Lonial, S, Russell, S J, Stewart, A K

“…Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in…”
Get full text

Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin by Elf, S, Lin, R, Xia, S, Pan, Y, Shan, C, Wu, S, Lonial, S, Gaddh, M, Arellano, M L, Khoury, H J, Khuri, F R, Lee, B H, Boggon, T J, Fan, J, Chen, J

“…The oxidative pentose phosphate pathway (PPP) is crucial for cancer cell metabolism and tumor growth. We recently reported that targeting a key oxidative PPP…”
Get full text

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax by Matulis, S M, Gupta, V A, Nooka, A K, Hollen, H V, Kaufman, J L, Lonial, S, Boise, L H

“…Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. The results…”
Get full text

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax by Bajpai, R, Matulis, S M, Wei, C, Nooka, A K, Von Hollen, H E, Lonial, S, Boise, L H, Shanmugam, M

“…Multiple myeloma (MM) is a plasma cell malignancy that is largely incurable due to development of resistance to therapy-elicited cell death. Nutrients are…”
Get full text

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma by Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C

“…This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in…”
Get full text

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients by Mazumder, A, Kaufman, J, Niesvizky, R, Lonial, S, Vesole, D, Jagannath, S

Get full text

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) by Ocio, E M, Richardson, P G, Rajkumar, S V, Palumbo, A, Mateos, M V, Orlowski, R, Kumar, S, Usmani, S, Roodman, D, Niesvizky, R, Einsele, H, Anderson, K C, Dimopoulos, M A, Avet-Loiseau, H, Mellqvist, U-H, Turesson, I, Merlini, G, Schots, R, McCarthy, P, Bergsagel, L, Chim, C S, Lahuerta, J J, Shah, J, Reiman, A, Mikhael, J, Zweegman, S, Lonial, S, Comenzo, R, Chng, W J, Moreau, P, Sonneveld, P, Ludwig, H, Durie, B G M, Miguel, J F S

“…Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs…”
Get full text

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma by Laganà, A, Perumal, D, Melnekoff, D, Readhead, B, Kidd, B A, Leshchenko, V, Kuo, P-Y, Keats, J, DeRome, M, Yesil, J, Auclair, D, Lonial, S, Chari, A, Cho, H J, Barlogie, B, Jagannath, S, Dudley, J T, Parekh, S

“…Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we…”
Get full text

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders by Dispenzieri, A, Kyle, R, Merlini, G, Miguel, J S, Ludwig, H, Hajek, R, Palumbo, A, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M, Comenzo, R, Einsele, H, Barlogie, B, Anderson, K, Gertz, M, Harousseau, J L, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Richardson, P, Sezer, O, Mateos, M V, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Rajkumar, S V, Durie, B G M

“…The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ immunoglobulin light chains. There are three major indications for the…”
Get full text

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma by Xu, XS, Yan, X, Puchalski, T, Lonial, S, Lokhorst, HM, Voorhees, PM, Plesner, T, Liu, K, Khan, I, Jansson, R, Ahmadi, T, Ruixo, JJ Perez, Zhou, H, Clemens, PL

“…New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human…”
Get full text

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study by Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I.

“…Background: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in…”
Get full text

Management of treatment-emergent peripheral neuropathy in multiple myeloma by Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, Sonneveld, P

“…Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects…”
Get full text

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma by Palumbo, A, Rajkumar, S V, Dimopoulos, M A, Richardson, P G, San Miguel, J, Barlogie, B, Harousseau, J, Zonder, J A, Cavo, M, Zangari, M, Attal, M, Belch, A, Knop, S, Joshua, D, Sezer, O, Ludwig, H, Vesole, D, Bladé, J, Kyle, R, Westin, J, Weber, D, Bringhen, S, Niesvizky, R, Waage, A, von Lilienfeld-Toal, M, Lonial, S, Morgan, G J, Orlowski, R Z, Shimizu, K, Anderson, K C, Boccadoro, M, Durie, B G, Sonneveld, P, Hussein, M A

“…The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer patients. The risk of VTE is…”
Get full text

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study by Jakubowiak, A J, Siegel, D S, Martin, T, Wang, M, Vij, R, Lonial, S, Trudel, S, Kukreti, V, Bahlis, N, Alsina, M, Chanan-Khan, A, Buadi, F, Reu, F J, Somlo, G, Zonder, J, Song, K, Stewart, A K, Stadtmauer, E, Harrison, B L, Wong, A F, Orlowski, R Z, Jagannath, S

“…Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities…”
Get full text